Shanghai Haohai Biological Technology Co., Ltd. Class H (HK:6826)
:6826
Want to see HK:6826 full AI Analyst Report?
Top Page
Shanghai Haohai Biological Technology Co., Ltd. Class H
(6826)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$23.00
â–Ľ(-7.63% Downside)
Action:ReiteratedDate:04/28/26
The score is driven mainly by solid underlying financial resilience (notably low leverage) and a supportive valuation/high dividend yield, but is held back by deteriorating operating momentum (flat-to-down revenue, margin compression, declining free cash flow) and clearly bearish technical trends with the price below all key moving averages.
Positive Factors
Conservative balance sheet / low leverage
Very low debt levels materially limit financial risk and preserve flexibility. This conservatism supports sustained investment capacity for R&D, capacity and distribution, and provides resilience through industry cycles, reducing likelihood of forced financing or distress.
Negative Factors
Recent revenue contraction
A material slowdown in top-line growth after prior expansion suggests waning demand or competitive pressure in core markets. Persistent or recurrent revenue declines would reduce headroom for reinvestment, hinder scale advantages, and constrain long-term growth potential.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low debt levels materially limit financial risk and preserve flexibility. This conservatism supports sustained investment capacity for R&D, capacity and distribution, and provides resilience through industry cycles, reducing likelihood of forced financing or distress.
Read all positive factors
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$9.56B
Dividend Yield4.28%
Average Volume (3M)211.55K
Price to Earnings (P/E)15.0
Beta (1Y)0.80
Revenue Growth-7.59%
EPS Growth-41.42%
CountryHK
Employees2,156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.37
Shares Outstanding35,929,040
10 Day Avg. Volume238,704
30 Day Avg. Volume211,551
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.94
Price to Sales (P/S)2.13
P/FCF Ratio11.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.72
Revenue Forecast (FY)HK$2.62B
Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Haohai Biological Technology Co., Ltd. is a leading biotechnology company based in Shanghai, China, specializing in the research, development, production, and commercialization of innovative medical devices and biopharmaceuticals. The com...
How the Company Makes Money
The company makes money mainly by selling its medical device and biomedical material products through hospital/clinic and distributor channels, with revenue recognized from product sales to customers. Key revenue streams typically include: (1) Oph...
Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
82
Very Positive
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.41B | 2.40B | 2.68B | 2.63B | 2.10B | 1.75B |
| Gross Profit | 1.62B | 1.56B | 1.87B | 1.85B | 1.45B | 1.26B |
| EBITDA | 217.64M | 480.36M | 549.05M | 713.41M | 447.55M | 550.45M |
| Net Income | 227.09M | 244.51M | 420.45M | 416.12M | 180.47M | 352.23M |
Balance Sheet | ||||||
| Total Assets | 6.64B | 6.72B | 7.12B | 7.11B | 6.89B | 6.95B |
| Cash, Cash Equivalents and Short-Term Investments | 2.40B | 2.52B | 2.76B | 2.75B | 2.56B | 2.91B |
| Total Debt | 416.01M | 398.67M | 448.43M | 407.95M | 118.26M | 105.51M |
| Total Liabilities | 1.06B | 1.12B | 1.20B | 1.09B | 990.02M | 890.07M |
| Stockholders Equity | 5.43B | 5.42B | 5.58B | 5.65B | 5.51B | 5.71B |
Cash Flow | ||||||
| Free Cash Flow | 343.10M | 446.40M | 283.08M | 367.22M | -85.85M | 70.19M |
| Operating Cash Flow | 585.92M | 628.50M | 648.57M | 634.45M | 231.30M | 342.29M |
| Investing Cash Flow | -330.41M | -10.81M | 282.28M | -376.65M | -681.82M | -148.09M |
| Financing Cash Flow | -499.55M | -509.70M | -390.35M | -257.73M | -288.35M | -231.25M |
Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis
Negative
24.90
Price Trends
24.26
Negative
25.23
Negative
26.29
Negative
Market Momentum
-0.65
Negative
33.18
Neutral
4.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6826, the sentiment is Negative. The current price of 24.9 is above the 20-day moving average (MA) of 22.56, above the 50-day MA of 24.26, and below the 200-day MA of 26.29, indicating a bearish trend. The MACD of -0.65 indicates Negative momentum. The RSI at 33.18 is Neutral, neither overbought nor oversold. The STOCH value of 4.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6826.
Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$24.51B | 73.24 | 8.62% | ― | 40.78% | 410.73% | |
62 Neutral | HK$9.56B | 15.02 | 4.50% | 4.28% | -7.59% | -41.42% | |
58 Neutral | HK$14.28B | -86.94 | -11.81% | ― | 219.26% | 87.63% | |
54 Neutral | HK$20.32B | -9.33 | -12.74% | ― | 57.92% | -23.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$10.16B | 30.77 | 24.17% | ― | 154.21% | ― | |
41 Neutral | HK$21.34B | -25.84 | -17.26% | ― | 66.66% | 7.19% |
* Healthcare Sector Average
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
21.88
-1.58
-6.73%
HK:1672
Ascletis Pharma, Inc.
17.91
11.23
168.11%
HK:2157
Lepu Biopharma Co. Ltd. Class H
5.57
0.97
21.09%
HK:2162
Keymed Biosciences, Inc.
75.65
30.65
68.11%
HK:2171
CARsgen Therapeutics Holdings Ltd.
24.18
8.20
51.31%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
58.85
46.79
387.98%
Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events
Haohai BioTech Sets 2025 AGM With Share Buyback Mandate and Governance Resolutions
Apr 28, 2026
Shanghai Haohai Biological Technology Co., Ltd. has called its 2025 annual general meeting for 29 May 2026 in Shanghai, where shareholders will review the 2025 board work report, financial report and profit distribution plan, and decide on directo...
Haohai Biological Calls 2026 H Shareholders’ Meeting to Seek 10% Buyback Mandate
Apr 28, 2026
Shanghai Haohai Biological Technology has called its first 2026 H shareholders’ class meeting for 29 May 2026 in Shanghai, to be held immediately after the 2025 annual general meeting and the first 2026 A shareholders’ class meeting. H...
Shanghai Haohai Biological Updates 2025 Final Dividend and Tax Arrangements
Apr 28, 2026
Shanghai Haohai Biological Technology Co., Ltd., a biotech and medical-focused H-share issuer in Hong Kong, has updated details of its final dividend for the financial year ended 31 December 2025. The company continues to position itself as an inc...
Shanghai Haohai Biological Technology Issues Unaudited Q1 2026 Financial Update
Apr 24, 2026
Shanghai Haohai Biological Technology Co., Ltd., a PRC-based joint stock company listed in Hong Kong under stock code 6826, operates in the biological technology sector through a group of subsidiaries. Its governance structure comprises executive,...
Shanghai Haohai Bolsters Senior Management With Three New Deputy General Managers
Apr 24, 2026
Shanghai Haohai Biological Technology Co., Ltd. has strengthened its senior management ranks by appointing three new deputy general managers following board and nomination committee approval on April 24, 2026. The appointments of industry veteran ...
Haohai Bio Tech Sets Formal Rules for Board Remuneration Committee
Apr 24, 2026
Shanghai Haohai Biological Technology has established a remuneration and appraisal committee under its board of directors to strengthen its remuneration management system and corporate governance. The committee is composed mainly of independent no...
Shanghai Haohai Biotech Revamps Board With New Executive and Independent Directors
Apr 24, 2026
Shanghai Haohai Biological Technology Co., Ltd. has proposed electing current board secretary and joint company secretary Tian Min as an additional executive director, reflecting efforts to enhance corporate governance, board diversity and long-te...
Shanghai Haohai Biological Schedules Board Meeting to Approve Q1 2026 Results
Apr 14, 2026
Shanghai Haohai Biological Technology Co., Ltd. has scheduled a board meeting for 24 April 2026 to review and approve its first-quarter results for the period ended 31 March 2026. The move signals the forthcoming release of the group’s quart...
Shanghai Haohai Cuts Capital After Cancelling Over 3.2 Million H Shares
Mar 20, 2026
Shanghai Haohai Biological Technology Co., Ltd. has adjusted its share capital structure following earlier issuances of A and H shares, and now reports a total of 229,980,895 shares, consisting of 194,051,855 A shares and 35,929,040 H shares. The ...
Shanghai Haohai Settles Profit Guarantee Adjustments in Ophthalmology Unit Acquisition
Mar 20, 2026
Shanghai Haohai Biological Technology announced the finalisation of profit guarantee arrangements tied to its staged acquisition of Shenzhen New Industries Material of Ophthalmology Co., Ltd., in which its wholly owned subsidiary agreed to buy equ...
Shanghai Haohai Profit Slumps in 2025 as Revenue Falls but Dividend Held Steady
Mar 20, 2026
Shanghai Haohai Biological Technology reported 2025 revenue of RMB2.45 billion, down 8.71% year on year, with net profit attributable to shareholders dropping 40.30% to RMB251.01 million and adjusted net profit down 57.67%. The company reduced RD ...
Shanghai Haohai Biological Proposes Final Dividend for 2025
Mar 20, 2026
Shanghai Haohai Biological Technology Co., Ltd. has proposed a final ordinary cash dividend of RMB 0.6 per share for the financial year ended 31 December 2025, subject to shareholders’ approval. The dividend will be paid in Hong Kong dollars...
Haohai Biological Sets March 2026 Board Meeting to Review 2025 Results and Dividend Plan
Mar 10, 2026
Shanghai Haohai Biological Technology Co., Ltd. has scheduled a board meeting for 20 March 2026 to review and approve the consolidated annual results for the year ended 31 December 2025. The board will also consider recommending a final dividend, ...
Shanghai Haohai Issues Preliminary 2025 Results Showing Profit Slide
Feb 27, 2026
Shanghai Haohai Biological Technology Co., Ltd. has reported preliminary unaudited figures for 2025 prepared under China Accounting Standards, indicating a decline in both revenue and profitability. The company cautioned investors that these numbe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.